Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2024-06-06 Annual Report
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
2024-06-06_Rapport annuel 2023_FR_final.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'RAPPORT FINANCIER 2023' and 'RAPPORT ANNUEL' (Annual Report). It contains a comprehensive table of contents covering board reports, financial statements, audit reports, governance, and notes to the financial statements for the fiscal year ending December 31, 2023. This matches the definition of a 10-K (Annual Report). FY 2023
2024-06-06 French
4.98.03 Biosenic SA - Rapport de carence_31122023_signed.pdf
Audit Report / Information Classification · 95% confidence The document is titled "RAPPORT DE CARENCE, ÉTABLI PAR LE COMMISSAIRE, DESTINÉ À L'ASSEMBLÉE GÉNÉRALE DE BIOSENIC SA POUR L'EXERCICE CLOS LE 31 DECEMBRE 2023" (Report of Deficiency, established by the Commissioner, intended for the General Meeting of BIOSENIC SA for the fiscal year ended December 31, 2023). This report explicitly states that the auditor (commissaire) has not yet received the annual accounts and is therefore unable to establish the required audit report for the general assembly. Although it relates to the annual audit and the AGM, its primary function is to report a failure to complete the audit process due to missing annual accounts, which falls under the scope of audit/accounting information rather than the final Annual Report (10-K) or the AGM presentation itself. Given the specific nature of reporting on the audit status and compliance with legal requirements regarding annual accounts, the most fitting category is Audit Report / Information (AR), as it is a formal report from the auditor concerning the annual financial statements, even if it's a deficiency report. It is not a full 10-K, nor is it a general AGM presentation (AGM-R). FY 2023
2024-06-06 French
2024-06-06_Annual Report 2023_EN_final.pdf
Annual Report Classification · 100% confidence The document is titled 'FINANCIAL REPORT 2023' and contains a comprehensive table of contents covering the Board of Directors' report, corporate governance, remuneration, share capital, and full consolidated financial statements (Statement of Financial Position, Comprehensive Income, Cash Flow, and Changes in Equity) for the year ending 31 December 2023. This structure is characteristic of an Annual Report (10-K equivalent for international entities). FY 2023
2024-06-06 English
2024-06-06_Rapport annuel 2023_FR_final.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'RAPPORT FINANCIER 2023' and 'RAPPORT ANNUEL' (Annual Report). It contains a comprehensive table of contents covering board reports, financial statements, audit reports, governance, and notes to the financial statements for the fiscal year ending December 31, 2023. This matches the definition of a 10-K (Annual Report). FY 2023
2024-06-06 French
BioS_Rapport spécial_Exec 2024 06 02.pdf
Board/Management Information Classification · 95% confidence The document is a special report prepared by the Board of Directors of BioSenic SA concerning the proposed issuance of new convertible bonds under the authorized capital framework. It references specific articles of the Belgian Companies and Associations Code (CSA) and details the terms, conditions, and justifications for the issuance, including subscription agreements and financial restructuring context. The document is a detailed report from the Board to shareholders about a capital increase operation and convertible bond issuance, including legal and financial implications. It is not a general annual report, earnings release, or a simple announcement. It is not a proxy solicitation or voting results announcement. It is not a certification or a short publication announcement. The content fits the category of a Board/Management Information document, as it involves detailed information from the Board about a significant financing operation and capital structure change, but it is not a pure capital/financing update announcement (which would be shorter and less detailed). Given the detailed nature and the focus on Board's special report under legal articles, the best fit is Board/Management Information (MANG).
2024-06-02 French
BIOS_PR_2024_May_Denominator_EN_FINAL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled "PRESS RELEASE – REGULATED INFORMATION" and its primary content details an "increase in the total number of voting rights and shares as a result of the issuance of new shares." It provides specific figures for share capital, total shares, and voting rights as of two different dates (April 30, 2024, and May 31, 2024). This directly relates to changes in the company's capital structure and share count, which falls under the 'Share Issue/Capital Change' category (SHA). Although it mentions regulated information, the core subject is the capital change itself, not just an announcement of a report (RPA) or a general regulatory filing (RNS).
2024-05-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.